Compare Repligen Corporation Common Stock (RGEN) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Sea Limited — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B), while Sea Limited trades at $95.84 (market cap $58.38B). The key difference: Sea Limited is far larger — about 5.2× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Sea Limited for 103 Days on average.
| RGEN | SE | |
|---|---|---|
Market Cap | $11.31B | $58.38B |
Volume | 1,216,919 | 3,918,232 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $165.70 |
52-Week Low | $102.87 | $78.16 |
Typical Hold Time | 0 Days | 103 Days |
Enterprise Value | $11.20B | $53.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Sea Limited (SE) trades at $95.93, showing minimal daily movement with a 0.05% gain. The stock faces bearish technical signals but maintains strong fundamental growth with revenue increasing from $12.4B in 2022 to $22.9B in 2025. Recent earnings show mixed results with Q4 2025 missing expectations but Q1 and Q2 2026 beating estimates. Analyst sentiment remains overwhelmingly positive with 72.7% buy ratings and a $153.67 consensus price target representing 60% upside potential.
Sea's investment case hinges on continued e-commerce and fintech expansion, though recent insider selling and competitive pressures pose risks. The company's improving profitability trajectory and strong cash flow generation support long-term growth prospects, but investors should monitor execution on Shopee's margin improvement and Garena's gaming segment stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
